Ethnobotanical treatment strategies against alzheimer's disease

Current Alzheimer Research

Volumn 9, Issue 1, 2012, Pages 67-85

  Howes, Melanie Jayne R ^a   Houghton, Peter J ^a,b  

^a JODRELL LABORATORY   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Alzheimer's disease; Bacopa; Crocus; Dementia; Ginkgo biloba; Melissa; Salvia; Traditional chinese medicine

Indexed keywords

ANTIOXIDANT; ASIATIC ACID; BACOPA MONNIERI EXTRACT; CANNABIDIOL; CANNABIS; CENTELLA ASIATICA EXTRACT; CROCIN; CROCUS SATIVUS EXTRACT; CURCUMA LONGA EXTRACT; CURCUMIN; DONEPEZIL; EPIMEDIUM EXTRACT; FLUOXETINE; GINKGO BILOBA EXTRACT; HONOKIOL; HUPERZINE A; ICARIIN; IMIPRAMINE; MAGNOLIA OFFICINALIS EXTRACT; MAGNOLOL; NABILONE; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT; PHYSOSTIGMINE; PLANT EXTRACT; RIVASTIGMINE; UNINDEXED DRUG; VINCA ALKALOID; VINCAMINE; VINPOCETINE;

ABSENCE OF SIDE EFFECTS; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ANXIETY DISORDER; BACOPA MONNIERI; CENTELLA ASIATICA; CHINESE MEDICINE; COGNITION; CROCUS SATIVUS; CURCUMA LONGA; DEPRESSION; DRUG EFFICACY; DRUG SAFETY; DRUG STRUCTURE; EPIMEDIUM; ETHNOBOTANY; GASTROINTESTINAL SYMPTOM; GINKGO BILOBA; HAMILTON SCALE; HUMAN; MEDICINAL PLANT; MILD COGNITIVE IMPAIRMENT; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PHYSOSTIGMA; PRIORITY JOURNAL; PSYCHOSIS; REVIEW; SALVIA; SLEEP DISORDER; TRANQUILIZING ACTIVITY;

ALZHEIMER DISEASE; ETHNOBOTANY; HUMANS; PHYTOTHERAPY; PLANT EXTRACTS;

EID: 84856505107     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720512799015046     Document Type: Review

References (224)

1. Chadwick DJ, Marsh J, Eds. Ethnobotany and the Search for New Drugs. CIBA Foundation Symposium 185 Chichester, UK: Wiley (1994).
2. Heinrich M, Barnes J, Gibbons S, Williamson EM. Ethnobotany and ethnopharmacology. In: Fundamentals of Pharmacognosy and Phytotherapy. London; Churchill Livingstone pp. 48-58 (2004).
3. Houghton PJ. Traditional plant medicines as a source of new drugs. In: (Ed: Evans WC). Trease and Evans Pharmacognosy (16th edition). London: Elsevier pp. 62-74 (2009).
4. Evans WC, Ed. Trease and Evans Pharmacognosy (16th edition). London: Elsevier (2009).
5. Ben Amar M. Cannabinoids in medicine: A review of their therapeutic potential. J Ethnopharmacol 105: 1-25 (2006).
6. Campbell VA, Gowran A. Alzheimer's disease; taking the edge off with cannabinoids? Br J Pharmacol 152: 655-62 (2007).
7. Esposito G, De Filippis D, Carnuccio R, Izzo AA, Iuvone T. The marijuana component cannabidiol inhibits β-amyloid-induced tau protein hyperphosphorylation through Wnt/β-catenin pathway rescue in PC12 cells. J Mol Med 84: 253-8 (2006).
8. Janero DR, Vadivel SK, Makriyannis A. Pharmacotherapeutic modulation of the endocannabinoid signalling system in psychiatric disorders: Drug-discovery strategies. Int Rev Psychiatry 21: 122-33 (2009).
9. Viveros MP, Marco EM, File SE. Endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav 81: 331-342 (2005).
10. Zuardi AW, Crippa JAS, Hallak JEC, Pinto JP, Chagas MHN, Rodrigues GGR, et al. Cannabidiol for the treatment of psychosis in Parkinson's disease. J Psychopharmacol 23: 979-83 (2009).
11. Zuardi AW, Crippa JA, Hallak JE, Moreira FA, Guimarães FS. Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res 39: 421-9 (2006).
12. Grotenhermen F. Cannabinoids. Curr Drug Targets CNS Neurol Disord 4: 507-30 (2005).
13. Krishnan S, Cairns R, Howard R. Cannabinoids for the treatment of dementia (Review). Cochrane Database Syst Rev 2: CD007204 (2009).
14. Auddy B, Ferreira M, Blasina F, Lafon L, Arredondo F, Dajas F, et al. Screening of antioxidant activity of three Indian medicinal plants, traditionally used for the management of neurodegenerative diseases. J Ethnopharmacol 84: 131-8 (2003).
15. Chinese Pharmacopoeia Commission. Pharmacopoeia of the People's Republic of China. China: People's Medical Publishing House (2005).
16. Kim J, Lee HJ, Lee KW. Naturally occurring phytochemicals for the prevention of Alzheimer's disease. J Neurochem 112: 1415-30 (2010).
17. Shimmyo Y, Kihara T, Akaike A, Niidome T, Sugimoto H, Shimmyo Y, et al. Epigallocatechin-3-gallate and curcumin suppress amyloid β-induced β-site APP cleaving enzyme-1 upregulation. Neuroreport 19: 1329-33 (2008).
18. Agrawal R, Mishra B, Tyagi E, Nath C, Shukla R. Effect of curcumin on brain insulin receptors and memory functions in STZ (ICV) induced dementia model of rat. Pharmacol Res 61: 247-52 (2010).
19. Perry E, Howes M-JR. Medicinal plants and dementia therapy: Herbal hopes for brain aging? CNS Neurosci Ther. In press (2011).
20. Baum L, Lam CWK, Cheung SK-K, Kwok T, Lui V, Tsoh J, et al. Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 28: 110-3 (2008).
21. Ma X, Tan C, Zhu D, Gang DR, Xiao P. Huperzine A from Huperzia species. An ethnopharmacolgical review. J Ethnopharmacol 113: 15-34 (2007).
22. Gomes NG, Campos MG, Orfão JM, Ribeiro CA. Plants with neurobiological activity as potential targets for drug discovery. Prog Neuropsychopharmacol Biol Psychiatry 33: 1372-89 (2009).
23. Williams P, Sorribas A, Howes M-JR. Natural products as a source of Alzheimer's drug leads. Nat Prod Rep 28: 48-77 (2011).
24. Howes M-JR, Houghton PJ. Plants used in Chinese and Indian traditional medicine for improvement of memory and cognitive function. Pharmacol Biochem Behav 75: 513-27 (2003).
25. Wang BS, Wang H, Wei ZH, Song YY, Zhang L, Chen HZ. Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: An updated meta-analysis. J Neural Transm 116: 457-65 (2009).
26. Pogačić Kramp V, Herrling P. List of drugs in development for neurodegenerative diseases: Update for June 2010. Neurodegener Dis 8: 44-94 (2010).
27. Li J, Wu HM, Zhou RL, Liu GJ, Dong BR. Huperzine A for Alzheimer's disease. Cochrane Database Syst Rev 2: CD005592 (2008).
28. Lee JW, Lee YK, Lee BJ, Nam S-Y. Lee SI, Kim YH, et al. Inhibitory effect of ethanol extract of Magnolia officinalis and 4-Omethylhonokiol on memory impairment and neuronal toxicity induced by β-amyloid. Pharmacol Biochem Behav 95: 31-40 (2010).
29. Hoi CP, Ho YP, Baum L, Chow AHL. Neuroprotective effect of honokiol and magnolol, compounds from Magnolia officinalis, on β-amyloid-induced toxicity in PC12 cells. Phytother Res 24: 1538-42 (2010).
30. Lee YK, Choi IS, Ban JO, Lee HJ, Lee US, Han SB, et al. 4-OMethylhonokiol attenuated β-amyloid-induced memory impairment through reduction of oxidative damages via inactivation of p38 MAP kinase. J Nutr Biochem. 22: 476-86 (2011).
31. Lee YJ, Choi IS, Park MH, Lee YM, Song JK, Kim YH, et al. 4-OMethylhonokiol attenuates memory impairment in presenilin 2 mutant mice through reduction of oxidative damage and inactivation of astrocytes and the ERK pathway. Free Rad Biol Med 50: 66-77 (2011).
32. Matsui N, Takahashi K, Takeichi M, Kuroshita T, Noguchi K, Yamazaki K, et al. Magnolol and honokiol prevent learning and memory impairment and cholinergic deficit in SAMP8 mice. Brain Res 1305: 108-17 (2009).
33. Chao LK, Liao P-C, Ho C-L, Wang EI-C, Chuang C-C, Chiu H-W, et al. Anti-inflammatory bioactivities of honokiol through inhibition of protein kinase C, mitogen-activated protein kinase, and the NF-κB pathway to reduce LPS-induced TNFα and NO expression. J Agric Food Chem 58: 3472-8 (2010).
34. Oh JH, Kang LL, Ban JO, Kim YH, Kim KH, Han SB, et al. Antiinflammatory effect of 4-O-methylhonokiol, a novel compound isolated from Magnolia officinalis through inhibition of NF-κB. Chem Biol Interact 180: 506-14 (2009).
35. Chang-Mu C, Jen-Kun L, Shing-Hwa L, Shoei-Yn L-S. Characterization of neurotoxic effects of NMDA and the novel neuroprotection by phytopolyphenols in mice. Behav Neurosci 124: 541-53 (2010).
36. Ma H, Kim C-S, Ma Y, Nam S-Y, Kim D-S, Woo S-S, et al. Magnolol enhances pentobarbital-induced sleeping behaviors: Possible involvement of GABAergic systems. Phytother Res 23: 1340-44 (2009).
37. Kalman DS, Feldman S, Feldman R, Schwartz HI, Krieger DR, Garrison R. Effect of a proprietary Magnolia and Phellodendron extract on stress levels in healthy women: A pilot, double-blind, placebo-controlled clinical trial. Nutr J 7: 11 (2008).
38. Houghton PJ, Ren YH, Howes MJ. Acetylcholinesterase inhibitors from plants and fungi. Nat Prod Rep 23: 181-99 (2006).
39. Yoshida S, Suzuki N. Antiamnesic and cholinomimetic side-effects of the cholinesterase inhibitors, physostigmine, tacrine and NIK- 247 in rats. Eur J Pharmacol 250: 117-24 (1993).
40. Coelho F, Birks J. Physostigmine for Alzheimer's disease. Cochrane Database Syst Rev 2: CD001499 (2001).
41. Khanavi M, Pourmoslemi S, Farahanikia B, Hadjiakhoondi A, Ostad SN. Cytotoxicity of Vinca minor. Pharm Biol 48: 96-100 (2010).
42. Merlini L, Pinza M. Trends in searching for new cognition enhancing drugs. Prog Neuropsychopharmacol Biol Psychiatry 13: S61-75 (1989).
43. Nicholson CD. Pharmacology of nootropics and metabolically active compounds in relation to their use in dementia. Psychopharmacology 101: 147-59 (1990).
44. Nyakas C, Felszeghy K, Szabó R, Keijser JN, Luiten PGM, Szombathelyi Z, et al. Neuroprotective effects of vinpocetine and its major metabolite cis-apovincaminic acid on NMDA-induced neurotoxicity in a rat entorhinal cortex lesion model. CNS Neurosci Ther 15: 89-99 (2009).
45. Deshmukh R, Sharma V, Mehan S, Sharma N, Bedi KL. Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine - a PDE1 inhibitor. Eur J Pharmacol 620: 49-56 (2009).
46. Akhondzadeh S, Abbasi SH. Herbal medicine in the treatment of Alzheimer's disease. Am J Alzheimers Dis Other Demen 21: 113-8 (2006).
47. Valikovics A. Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions. Ideggyogy Sz. 60: 301-10 (2007).
48. Szatmari SZ, Whitehouse PJ. Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst Rev 1: CD003119 (2003).
49. de Caires S, Steenkamp V. Use of Yokukansan (TJ-54) in the treatment of neurological disorders: A review. Phytother Res 24: 1265-70 (2010).
50. Houghton PJ. The scientific basis for the reputed activity of Valerian. J Pharm Pharmacol 51: 505-12 (1999).
51. Williamson EM. Synergy and other interactions in phytomedicines. Phytomedicine 8: 401-9 (2001).
52. Williamson EM. Synergy in relation to the pharmacological action of phytomedicinals. In: (Ed: Evans WC). Trease and Evans Pharmacognosy (16th edition). London: Elsevier pp. 53-61 (2009).
53. Houghton PJ, Howes M-J, Lee CC, Steventon G Uses and abuses of in vitro tests in ethnopharmacology: Visualising an elephant. J. Ethnopharmacol 110: 391-400 (2007).
54. Houghton PJ, Hylands PJ, Mensah AY, Hensel A, Deters AM. In vitro tests and ethnopharmacological investigations: Wound healing as an example. J Ethnopharmacol 100: 100-7 (2005).
55. Williamson, EM. Potter's Herbal Cyclopedia. Saffron Walden: CW Daniel. pp. 38 (2003).
56. Nadkarni, AK. Indian Materia Medica (3rd Edition). Bombay: Popular Prakashan pp. 624-5 (1976).
57. Singh HK, Dhawan BN. Effect of Bacopa monniera L. (brahmi) extract on avoidance responses in rat. J Ethnopharmacol 5: 205-214 (1982).
58. Das A, Shankar G, Nath C, Pal R, Singh S, Singh HK. A comparative study in rodents of standardized extracts of Bacopa monniera and Ginkgo biloba anticholinesterase and cognitive enhancing activities. Pharmacol Biochem Behav 73: 893-900 (2002).
59. Hota SK, Barhwal K, Baitharu I, Prasad D, Singh SB, Ilavazhagan G. Bacopa monniera leaf extract ameliorates hypobaric hypoxia induced memory impairment. Neurobiol Disease 34: 23-9 (2009).
60. Prabhakar S, Saraf MK, Pandhi P, Anand A. Bacopa monniera exerts antiamnesic effect on diazepam-induced anterograde amnesia in mice. Psychopharmacology 200: 27-37 (2008).
61. Stough C, Lloyd J, Clarke J. The chronic effects of an extract of Bacopa monniera (brahmi) on cognitive function in healthy human subjects. Psychopharmacology 156: 481-4 (2001).
62. Raghav S, Singh H, Dalal PK, Srivasta JS, Asthana OP. Randomized controlled trial of standardized Bacopa monniera extract in age-associated memory impairment. Ind J Psychiatry 48: 238-42 (2006).
63. Stough C, Downey LA, Lloyd J, Silber B, Redman S, Hutchison C, et al. Examining the nootropic effects of a special extract of Bacopa monniera on human cognitive functioning: 90 day doubleblind placebo-controlled randomized trial. Phytother Res 22: 1629-34 (2008).
64. Morgan A, Stevens J. Does Bacopa monnieri improve memory performance in older persons? Results of a randomized, placebocontrolled, double-blind trial. J Altern Complement Med 16: 753-9 (2010).
65. Pravina K, Ravindra KR, Goudar KS, Vinod DR, Joshua AJ, Venkateshwarlu K, et al. Safety evaluation of BacoMind ™ in healthy volunteers: A phase 1 study. Phytomedicine 14: 301-8 (2007).
66. Bhattacharya SK, Bhattacharya A, Kumar A, Ghosal S. Antioxidant activity of Bacopa monniera in rat frontal cortex, striatum and hippocampus. Phytother Res 14: 174-9 (2000).
67. Zhou Y, Peng L, Zhang WD, Kong DY. Effect of triterpenoid saponins from Bacopa monniera on scopolamine-induced memory impairment in mice. Planta Med 75: 568-574 (2009).
68. Jyoti A, Sethi P, Sharma D. Bacopa monniera prevents from aluminium neurotoxicity in the cerebral cortex of rat brain. J Ethnopharmacol 111: 56-62 (2007).
69. Dhanasekaran M, Tharakan B, Holcomb LA, Hitt AR, Young KA, Manyam BV. Neuroprotective mechanisms of ayurvedic antidementia botanical Bacopa monniera. Phytother Res 21: 965-7 (2007).
70. Anand A, Saraf MK, Prabhakar S. Effect of B. monniera on LNNA- induced amnesia involves calmodulin. Neurochem Res 35: 1172-81 (2010).
71. Saraf MK, Anand A, Prabhakar S. Scopolamine-induced amnesia is reversed by Bacopa monniera through participation of kinase- CREB pathway. Neurochem Res 35: 279-87 (2010).
72. Chatterjee M, Verma P, Palit G. Comparative evaluation of Bacopa monniera and Panax quinquefolium in experimental anxiety and depressive models in mice. Ind J Exp Biol 48: 306-13 (2010).
73. Howes M-JR, Houghton PJ. Traditional medicine for memory enhancement. In: (Ed: Ramawat KG). Herbal Drugs: Ethnomedicine to Modern Medicine. New York: Springer pp. 239-91 (2009).
74. Adams M, Gmünder F, Hamburger M. Plants traditionally used in age related brain disorders - A survey of ethnobotanical literature. J Ethnopharmacol 113: 363-81 (2007).
75. Rao SB, Chetana M, Uma Devi P. Centella asiatica treatment during postnatal period enhances learning and memory in mice. Physiol Behav 86: 449-57 (2005).
76. Veerendra Kumar MH, Gupta YK. Effect of Centella asiatica on cognition and oxidative stress in an intracerebroventricular streptozotocin model of Alzheimer's disease in rats. Clin Exp Pharmacol Physiol 30: 336-42 (2003).
77. Nasir MN, Habsah M, Zamzuri I, Rammes G, Hasnan J, Abdullah J. Effects of asiatic acid on passive and active avoidance task in male Spraque-Dawley rats. J Ethnopharmacol 134: 203-9 (2011).
78. Subathra M, Shila S, Devi MA, Panneerselvam C. Emerging role of Centella asiatica in improving age-related neurological antioxidant status. Exp Gerontol 40: 707-15 (2005).
79. Shinomol GK, Muralidhara. Prophylactic neuroprotective property of Centella asiatica against 3-nitropropionic acid induced oxidative stress and mitochondrial dysfunctions in brain regions of prepubertal mice. Neurotoxicology 29: 948-57 (2008).
80. Shinomol GK, Muralidhara. Effect of Centella asiatica leaf powder on oxidative markers in brain regions of prepubertal mice in vivo and its in vitro efficacy to ameliorate 3-NPA-induced oxidative stress in mitochondria. Phytomedicine 15: 971-84 (2008).
81. Shinomol GK, Ravikumar H, Muralidhara. Prophylaxis with Centella asiatica confers protection to prepubertal mice against 3- nitropropionic-acid-induced oxidative stress in brain. Phytother Res 24: 885-92 (2010).
82. Dhanasekaran M, Holcomb LA, Hitt AR, Tharakan B, Porter JW, Young KA, et al. Centella asiatica extract selectively decreases amyloid β levels in hippocampus of Alzheimer's disease animal model. Phytother Res 23: 14-19 (2009).
83. Patil SP, Maki S, Khedkar SA, Rigby AC, Chan C. Withanolide A and asiatic acid modulate multiple targets associated with amyloid- β precursor protein processing and amyloid-β protein clearance. J Nat Prod 73: 1196-202 (2010).
84. Mook-Jung I, Shin JE, Yun SH, Huh K, Koh JY, Park HK, Jew SS, Jung MW. Protective effects of asiaticoside derivatives against β- amyloid neurotoxicity. J Neurosci Res 58: 417-25 (1999).
85. Lee MK, Kim SR, Sung SH, Lim DY, Kim H, Choi H, et al. Asiatic acid derivatives protect cultured cortical neurons from glutamate- induced excitotoxicity. Res Commun Mol Pathol Pharmacol 108: 75-86 (2000).
86. Mohandas Rao KG, Muddanna Rao S, Gurumadhva Rao S. Centella asiatica (L.) leaf extract treatment during the growth spurt period enhances hippocampal CA3 neuronal dendritic aborization in rats. Evid Based Complement Alternat Med 3: 349-57 (2006).
87. Soumyanath A, Zhong YP, Gold SA, Yu X, Koop DR, Bourdette D, et al. Centella asiatica accelerates nerve regeneration upon oral administration and contains multiple active fractions increasing neurite elongation in vitro. J Pharm Pharmacol 57: 1221-9 (2005).
88. Mukherjee PK, Kumar V, Houghton PH. Screening of Indian medicinal plants for acetylcholinesterase inhibitory activity. Phytother Res 21: 1142-5 (2007).
89. Visweswari G, Prasad KS, Chetan PS, Lokanatha V, Rajendra W. Evaluation of the anticonvulsant effect of Centella asiatica (gotu kola) in pentylenetetrazol-induced seizures with respect to cholinergic neurotransmission. Epilepsy Behav 17: 332-5 (2010).
90. Awad R, Levac D, Cybulska P, Merali Z, Trudeau VL, Arnason JT. Effects of traditionally used anxiolytic botanicals on enzymes of the γ-aminobutyric acid (GABA) system. Can J Physiol Pharmacol 85: 933-942 (2007).
91. Chen SW, Wang WJ, Li WJ, Wang R, Li YL, Huang YN, et al. Anxiolytic-like effect of asiaticoside in mice. Pharmacol Biochem Behav 85: 339-44 (2006).
92. Wijeweera P, Arnason JT, Koszycki D, Merali Z. Evaluation of anxiolytic properties of Gotukola - (Centella asiatica) extracts and asiaticoside in rat behavioral models. Phytomedicine 13: 668-76 (2006).
93. Ernst E. Herbal remedies for anxiety - A systematic review of controlled clinical trials. Phytomedicine. 13: 205-8 (2006).
94. Jana U, Sur TK, Maity LN, Debnath PK, Bhattacharyya D. A clinical study on the management of generalized anxiety disorder with Centella asiatica. Nepal Med Coll J 12: 8-11 (2010).
95. Dev RDO, Mohamed S, Hambali Z, Samah BA. Comparison on cognitive effects of Centella asiatica in healthy middle age female and male volunteers. Eur J Sci Res 31: 553-65 (2009).
96. Wattanathorn J, Mator L, Muchimapura S, Tongun T, Pasuriwong O, Piyawatkul N, et al. Positive modulation of cognition and mood in the healthy elderly volunteer following the administration of Centella asiatica. J Ethnopharmacol 116: 325-32 (2008).
97. Lechtenberg M, Schepmann D, Niehues M, Hellenbrand N, Wünsch B, Hensel A. Quality and functionality of saffron: Quality control, species assortment and affinity of extract and isolated saffron compounds to NMDA and σ1 receptors. Planta Med 74: 764-72 (2008).
98. Akhondzadeh S, Tahmacebi-Pour N, Noorbala AA, Amini H, Fallah- Pour H, Jamshidi AH, et al. Crocus sativus L. in the treatment of mild to moderate depression: A double-blind, randomized and placebo-controlled trial. Phytother Res 19: 148-51 (2005).
99. Noorbala AA, Tahmasebi-Pour N, Akhondzadeh S, Khani M, Jamshidi AH. Crocus sativus L. in the treatment of mild to moderate depression: A double-blind, randomised and placebo controlled trial. J Med Plants 3: 31-38 (2004).
100. Akhondzadeh S, Fallah-Pour H, Afkham K, Jamshidi A-H, Khalighi-Cigaroudi F. Comparison of Crocus sativus L. and imipramine in the treatment of mild to moderate depression: A pilot double-blind randomized trial [ISRCTN45683816]. BMC Complement Altern Med 4: 12 (2004).
101. Noorbala AA, Akhondzadeh S, Tahmacebi-Pour N, Jamshidi AH. Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine in the treatment of mild to moderate depression: A double-blind, randomized pilot trial. J Ethnopharmacol 97: 281-4 (2005).
102. Moshiri E, Basti AA, Noorbala A-A, Jamshidi A-H, Hesameddin Abbasi S, Akhondzadeh S. Crocus sativus L. (petal) in the treatment of mild-to-moderate depression: A double-blind, randomized and placebo-controlled trial. Phytomedicine 13: 607-11 (2006).
103. Akhondzadeh Basti A, Moshiri E, Noorbala A-A, Jamshidi A-H, Abbasi SH, Akhondzadeh S. Comparison of petal of Crocus sativus L. and fluoxetine in the treatment of depressed outpatients: A pilot double-blind randomized trial. Progress Neuro-psychopharmacol Biol Psychiatry 31: 439-42 (2007).
104. Termentzi A, Kokkalou E. LC-DAD-MS (ESI+) analysis and antioxidant capacity of Crocus sativus petal extracts. Planta Med 74: 573-81 (2008).
105. Hosseinzadeh H, Noraei NB. Anxiolytic and hypnotic effect of Crocus sativus aqueous extract and its constituents, crocin and safranal, in mice. Phytother Res 23: 768-74 (2009).
106. Akhondzadeh S, Shafiee Sabet M, Harirchian MH, Togha M, Cheraghmakani H, Razeghi S, et al. A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer's disease. Psychopharmacology 207: 637-43 (2010).
107. Akhondzadeh S, Sabet MS, Harirchian MH, Togha M, Cheraghmakani H, Razeghi S, et al. Saffron in the treatment of patients with mild to moderate Alzheimer's disease: A 16-week, randomized and placebo-controlled trial. J Clin Pharm Ther 35: 581-8 (2010).
108. Soeda S, Ochiai T, Paopong L, Tanaka H, Shoyama Y, Shimeno H. Crocin suppresses tumor necrosis factor-α-induced cell death of neuronally differentiated PC-12 cells. Life Sci 69: 2887-98 (2001).
109. Ochiai T, Shimeno H, Mishima K, Iwasaki K, Fujiwara M, Tanaka H, et al. Protective effects of carotenoids from saffron on neuronal injury in vitro and in vivo. Biochim Biophys Acta 1770: 578-84 (2007).
110. Ochiai T, Ohno S, Soeda S, Tanaka H, Shoyama Y, Shimeno H. Crocin prevents the death of rat pheochromyctoma (PC-12) cells by its antioxidant effects stronger than those of α-tocopherol. Neurosci Lett 362: 61-4 (2004).
111. Ochiai T, Soeda S, Ohno S, Tanaka H, Shoyama Y, Shimeno H. Crocin prevents the death of PC-12 cells through sphingomyelinase- ceramide signaling by increasing glutathione synthesis. Neurochem Int 44: 321-30 (2004).
112. Mousavi SH, Tayarani NZ, Parsaee H. Protective effect of saffron extract and crocin on reactive oxygen species-mediated high glucose- induced toxicity in PC12 cells. Cell Mol Neurobiol 30: 185-91 (2010).
113. Nam KN, Park YM, Jung HJ, Lee JY, Min BD, Park SU, et al. Anti-inflammatory effects of crocin and crocetin in rat brain microglial cells. Eur J Pharmacol 648: 110-6 (2010).
114. Zheng Y-Q, Liu J-X, Wang J-N, Xu L. Effects of crocin on reperfusion- induced oxidative/nitrative injury to cerebral microvessels after global cerebral ischemia. Brain Res 1138: 86-94 (2007).
115. Pitsikas N, Zisopoulou S, Tarantilis PA, Kanakis CD, Polissiou MG, Sakellaridis N. Effects of the active constituents of Crocus sativus L., crocins on recognition and spatial rats' memory. Behav Brain Res 183: 141-6 (2007).
116. Ghadami MR, Pourmotabbed A. The effect of crocin on scopolamine induced spatial learning and memory deficits in rats. Physiol Pharmacol 12: 287-95 (2009).
117. Papandreou MA, Kanakis CD, Polissiou MG, Efthimiopoulos S, Cordopatis P, Margarity M, et al. Inhibitory activity on amyloid-β aggregation and antioxidant properties of Crocus sativus stigmas extract and its crocin constituents. J Agric Food Chem 54: 8762-8 (2006).
118. Ahmad AS, Ansari MA, Ahmad M, Saleem S, Yousuf S, Hoda MN, et al. Neuroprotection by crocetin in a hemi-parkinsonian rat model. Pharmacol Biochem Behav 81: 805-13 (2005).
119. Li L, Zhou QX, Shi JS. Protective effects of icariin on neurons injured by cerebral ischemia/reperfusion. Chin Med J 118: 1637-43 (2005).
120. Xu RX, Wu Q, Luo Y, Gong QH, Yu LM, Huang XN, et al. Protective effects of icariin on cognitive deficits induced by chronic cerebral hypoperfusion in rats. Clin Exp Pharmacol Physiol 36: 810-5 (2009).
121. Li F, Gong QH, Wu Q, Lu YF, Shi JS. Icariin isolated from Epimedium brevicornum Maxim attenuates learning and memory deficits induced by D-galactose. Pharmacol Biochem Behav 96: 301-5 (2010).
122. Urano T, Tohda C. Icariin improves memory impairment in Alzheimer's disease model mice (5xFAD) and attenuates amyloid β- induced neurite atrophy. Phytother Res 24: 1658-63 (2010).
123. Zeng KW, Ko H, Yang HO, Wang XM. Icariin attenuates β- amyloid-induced neurotoxicity by inhibition of tau protein hyperphosphorylation in PC12 cells. Neuropharmacology 59: 542-50 (2010).
124. Oh MH, Houghton PJ, Whang WK, Cho JH. Screening of Korean herbal medicines used to improve cognitive function for anticholinesterase activity. Phytomedicine 11: 544-8 (2004).
125. Houghton PJ, Howes M-JR. Use of plants for management of Alzheimer's disease. In (Eds: Fingerman M, Nagabhushanam R) Biomaterials from Aquatic and Terrestrial Organisms. Enfield (NH) USA: Science Publishers pp. 1-36 (2006).
126. Barnes J, Anderson LA, Phillipson JD. Herbal Medicines (3rd Edition). London: Pharmaceutical Press (2007).
127. Canter PH, Ernst E. Ginkgo biloba: A smart drug? A systematic review of controlled trials of the cognitive effects of Ginkgo biloba extracts on healthy people. Psychopharmacology Bull 36: 108-23 (2002).
128. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF. A placebo-controlled, double-blind randomized trial of an extract of Ginkgo biloba for dementia. JAMA 278: 1327-1332 (1997).
129. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 4: CD003120 (2002).
130. Birks J, Grimley Evans J. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev 1: CD003120 (2009).
131. Napryeyenko O, Sonik G, Tartakovsky I. Efficacy and tolerability of Ginkgo biloba extract EGb 761® by type of dementia: Analyses of a randomised controlled trial. J Neurol Sci 283: 224-9 (2009).
132. Wang BS, Wang H, Song YY, Qi H, Rong ZX, Wang BS, et al. Effectiveness of standardised Ginkgo biloba extract on cognitive symptoms of dementia with a six-month treatment: A bivariate random effect meta-analysis. Pharmacopsychiatry 43: 86-91 (2010).
133. Shi C, Zhao LN, Zhu BL, Li QX, Yew DT, Yao ZB, et al. Protective effects of Ginkgo biloba extract (EGb761) and its constituents quercetin and ginkgolide B against β-amyloid peptide-induced toxicity in SH-SY5Y cells. Chem Biol Interact 181: 115-23 (2009).
134. Hou Y, Aboukhatwa MA, Lei DL, Manaye K, Khan I, Luo Y. Anti-depressant natural flavonoids modulate BDNF and β-amyloid in neurons and hippocampus of double TgAD mice. Neuropharmacology 58: 911-20 (2010).
135. Yoshitake T, Yoshitake S, Kehr J. The Ginkgo biloba extract EGb761® and its main constituent flavonoids and ginkgolides increase extracellular dopamine levels in the rat prefrontal cortex. Brit J Pharmacol 159: 659-68 (2010).
136. Francis PT, Ramírez MJ, Lai MK. Neurochemical basis for symptomatic treatment of Alzheimer's disease. Neuropharmacology 59: 221-9 (2010).
137. Tchantchou F, Lacor PN, Cao ZM, Lao LX, Hou Y, Cui CH, et al. Stimulation of neurogenesis and synaptogenesis by bilobalide and quercetin via common final pathway in hippocampal neurons. J Alzheimers Dis 18: 787-98 (2009).
138. Bate C, Tayebi M, Williams A. Ginkgolides protect against amyloid- β(1-42)-mediated synapse damage in vitro. Mol Neurodegen 3: 1 (2008).
139. Vitolo O, Gong B, Cao ZX, Ishii H, Jaracz S, Nakanishi K, et al. Protection against β-amyloid induced abnormal synaptic function and cell death by ginkgolide J. Neurobiol Aging 30: 257-65 (2009).
140. Li LY, Zhao XL, Fei XF, Gu ZL, Qin ZH, Liang ZQ. Bilobalide inhibits 6-OHDA-induced activation of NF-κB and loss of dopaminergic neurons in rat substantia nigra. Acta Pharmacol Sin 29: 539-47 (2008).
141. Ferreira A, Proença C, Serralheiro ML, Araújo ME. The in vitro screening for acetylcholinesterase inhibition and antioxidant activity of medicinal plants from Portugal. J Ethnopharmacol 108: 31-7 (2006).
142. Adsersen A, Gauguin B, Gudiksen L, Jäger AK. Screening of plants used in Danish folk medicine to treat memory dysfunction for acetylcholinesterase inhibitory activity. J Ethnopharmacol 104: 418-22 (2006).
143. Perry N, Court G, Bidet N, Court J, Perry E. European herbs with cholinergic activities: Potential in dementia therapy. Int J Geriatr Psychiatry 11: 1063-9 (1996).
144. Wake G, Court J, Pickering A, Lewis R, Wilkins R, Perry E. CNS acetylcholine receptor activity in European medicinal plants traditionally used to improve failing memory. J Ethnopharmacol 69: 105-14 (2000).
145. Elliott MSJ, Abuhamdah S, Howes M-JR, Lees G, Ballard CG, Holmes C, et al. The essential oils from Melissa officinalis L. and Lavandula angustifolia Mill. as potential treatment for agitation in people with severe dementia. Int J Essent Oil Ther 1: 143-52 (2007).
146. Howes MJ, Houghton PJ, Barlow DJ, Pocock VJ, Milligan SR. Assessment of estrogenic activity in some common essential oil constituents. J Pharm Pharmacol 54: 1521-8 (2002).
147. Kennedy DO, Scholey AB, Tildesley NT, Perry EK, Wesnes KA. Modulation of mood and cognitive performance following acute administration of Melissa officinalis (lemon balm). Pharmacol Biochem Behav 72: 953-64 (2002).
148. Kennedy DO, Wake G, Savelev S, Tildesley NT, Perry EK, Wesnes KA, et al. Modulation of mood and cognitive performance following acute administration of single doses of Melissa officinalis (lemon balm) with human CNS nicotinic and muscarinic receptorbinding properties. Neuropsychopharmacology 28: 1871-81 (2003).
149. Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M. Melissa officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: A double blind, randomised, placebo controlled trial. J Neurol Neurosurg Psychiatry 74: 863-6 (2003).
150. Kennedy DO, Little W, Scholey AB. Attenuation of laboratoryinduced stress in humans after acute administration of Melissa officinalis (lemon balm). Psychosom Med 66: 607-13 (2004).
151. Cases J, Ibarra A, Feuillère N, Roller M, Sukkar SG. Pilot trial of Melissa officinalis L. leaf extract in the treatment of volunteers suffering from mild-to-moderate anxiety disorders and sleep disturbances. Mediterr J Nutr Metab. In press.
152. Ballard CG, O'Brien JT, Reichelt K, Perry EK. Aromatherapy as a safe and effective treatment for the management of agitation in severe dementia: The results of a double-blind, placebo-controlled trial with melissa. J Clin Psychiatry 63: 553-8 (2002).
153. Thorgrimsen L, Spector A, Wiles A, Orrell M. Aroma therapy for dementia. Cochrane Database Syst Rev 3: CD003150 (2003).
154. Huang L, Abuhamdah S, Howes MJ, Dixon CL, Elliot MS, Ballard C, et al. Pharmacological profile of essential oils derived from Lavandula angustifolia and Melissa officinalis with anti-agitation properties: Focus on ligand-gated channels. J Pharm Pharmacol 60: 1515-22 (2008).
155. Abuhamdah S, Huang L, Elliott MS, Howes MJ, Ballard C, Holmes C, et al. Pharmacological profile of an essential oil derived from Melissa officinalis with anti-agitation properties: Focus on ligand-gated channels. J Pharm Pharmacol 60: 377-84 (2008).
156. Burns A, Perry E, Holmes C, Francis P, Morris J, Howes M-JR, et al. A double blind placebo controlled randomised trial of Melissa officinalis oil and donepezil for the treatment of agitation in Alzheimer's disease. Dement Geriatr Cogn Disord 31: 158-64 (2011).
157. Chen YJ, Huang XB, Li ZX, Yin LL, Chen WQ, Li L. Tenuigenin protects cultured hippocampal neurons against methylglyoxalinduced neurotoxicity. Eur J Pharmacol 645: 1-8 (2010).
158. Jia H, Jiang Y, Ruan Y, Zhang Y, Ma X, Zhang J, et al. Tenuigenin treatment decreases secretion of the Alzheimer's disease amyloid β- protein in cultured cells. Neurosci Lett 367: 123-8 (2004).
159. Lv J, Jia H, Jiang Y, Ruan Y, Liu Z, Yue W, et al. Tenuifolin, an extract derived from tenuigenin, inhibits amyloid-β secretion in vitro. Acta Physiol 196: 419-25 (2009).
160. Zhang H, Han T, Zhang L, Yu CH, Wan DG, Rahman K, et al. Effects of tenuifolin extracted from radix polygalae on learning and memory: A behavioral and biochemical study on aged and amnesic mice. Phytomedicine 15: 587-94 (2008).
161. Xu XH, Zhou JF, Li TZ, Zhang ZH, Shan L, Xiang ZH, et al. Polygalasaponin G promotes neurite outgrowth of cultured neuron on myelin. Neurosci Lett 460: 41-6 (2009).
162. Yao Y, Jia M, Wu JG, Zhang H, Sun LN, Chen WS, et al. Anxiolytic and sedative-hypnotic activities of polygalasaponins from Polygala tenuifolia in mice. Pharm Biol 48: 801-7 (2010).
163. Chung IW, Moore NA, Oh WK, O'Neill MF, Ahn JS, Park JB, et al. Behavioural pharmacology of polygalasaponins indicates potential antipsychotic efficacy. Pharmacol Biochem Behav 71: 191-5 (2002).
164. Xue W, Hu JF, Yuan YH, Sun JD, Li BY, Zhang DM, et al. Polygalasaponin XXXII from Polygala tenuifolia root improves hippocampal-dependent learning and memory. Acta Pharmacol Sin 30: 1211-9 (2009).
165. Yabe T, Tuchida H, Kiyohara H, Takeda T, Yamada H. Induction of NGF synthesis in astrocytes by onjisaponins of Polygala tenuifolia, constituents of kampo (Japanese herbal) medicine, Ninjin-yoeito. Phytomedicine 10: 106-14 (2003).
166. Li C, Yang J, Yu S, Chen N, Xue W, Hu J, et al. Triterpenoid saponins with neuroprotective effects from the roots of Polygala tenuifolia. Planta Med 74: 133-41 (2008).
167. Karakida F, Ikeya Y, Tsunakawa M, Yamaguchi T, Ikarashi Y, Takeda S, et al. Cerebral protective and cognition-improving effects of sinapic acid in rodents. Biol Pharm Bull 30: 514-9 (2007).
168. Hu Y, Liao HB, Dai-Hong G, Liu P, Wang YY, Rahman K. Antidepressant-like effects of 3,6'-disinapoyl sucrose on hippocampal neuronal plasticity and neurotrophic signal pathway in chronically mild stressed rats. Neurochem Int. 56: 461-5 (2010).
169. Liu P, Hu Y, Guo DH, Lu BR, Rahman K, Mu LH, et al. Antioxidant activity of oligosaccharide ester extracted from Polygala tenuifolia roots in senescence-accelerated mice. Pharm Biol 48: 828-33 (2010).
170. Cheng MC, Li CY, Ko HC, Ko FN, Lin YL, Wu TS. Antidepressant principles of the roots of Polygala tenuifolia. J Nat Prod 69: 1305-9 (2006).
171. Howes M-JR, Perry NSL, Houghton PJ. Plants with traditional uses and activities, relevant to the management of Alzheimer's disease and other cognitive disorders. Phytother Res 17: 1-18 (2003).
172. Nah S-Y, Kim D-H, Rhim H. Ginsenosides: Are any of them candidates for drugs acting on the central nervous system? CNS Drug Rev 13: 381-404 (2007).
173. Radad K, Gille G, Liu L, Rausch W-D. Use of ginseng in medicine with emphasis on neurodegenerative disorders. J Pharmacol Sci 100: 175-86 (2006).
174. Oh MS, Huh Y, Bae H, Ahn DK, Park SK. The multi-herbal formula Guibi-tang enhances memory and increases cell proliferation in the rat hippocampus. Neurosci Lett 379: 205-8 (2005).
175. Chen YL, Hseih CL, Wu PH, Lin JG. Effect of Polygala tenuifolia root on behavioural disorders by lesioning nucleus basalis magnocellularis. J Ethnopharmacol 95: 47-55 (2004).
176. Park CH, Choi SH, Koo JW, Seo JH, Kim HS, Jeong SJ, et al. Novel cognitive improving and neuroprotective activities of Polygala tenuifolia Willdenow extract, BT-11. J Neurosci Res 70: 484-92 (2002).
177. Shin KY, Won BY, Heo C, Kim HJ, Jang DP, Park CH, et al. BT- 11 improves stress-induced memory impairments through increment of glucose utilization and total neural cell adhesion molecule levels in rat brains. J Neurosci Res 87: 260-8 (2009).
178. Park HJ, Lee K, Heo H, Lee M, Kim JW, Whang WW, et al. Effects of Polygala tenuifolia root extract on proliferation of neural stem cells in the hippocampal CA1 region. Phytother Res 22: 1324-9 (2008).
179. Lee HJ, Ban JY, Koh SB, Seong NS, Song KS, Bae KW, et al. Polygalae radix extract protects cultured rat granule cells against damage induced by NMDA. Am J Chin Med 32: 599-610 (2004).
180. Naito R, Tohda C. Characterization of anti-neurodegenerative effects of Polygala tenuifolia in Aβ(25-35)-treated cortical neurons. Biol Pharm Bull 29: 1892-6 (2006).
181. Kim HM, Lee EH, Na HJ, Lee SB, Shin TY, Lyu YS, et al. Effect of Polygala tenuifolia root extract on the tumor necrosis factor-α secretion from mouse astrocytes. J Ethnopharmacol 61: 201-8 (1998).
182. Lee J-Y, Kim KY, Shin KY, Won BY, Jung HY, Suh YH. Effects of BT-11 on memory in healthy humans. Neurosci Lett 454: 111-4 (2009).
183. Shin KY, Lee J-Y, Won BY, Jung HY, Chang K-A, Koppula S, et al. BT-11 is effective for enhancing cognitive functions in the elderly humans. Neurosci Lett 465: 157-9 (2009).
184. Arai H, Suzuki T, Sasaki H, Hanawa T, Toriizuka K, Yamada H. A new interventional strategy for Alzheimer's disease by Japanese herbal medicine. Japanese J Geriatr 37: 212-5 (2000).
185. Maruyama M, Tomita N, Iwasaki K, Ootsuki M, Matsui T, Nemoto M, et al. Benefits of combining donepezil plus traditional Japanese herbal medicine on cognition and brain perfusion in Alzheimer's disease: A 12-week observer-blind, donepezil monotherapy controlled trial. J Am Geriatr Soc 54: 869-71 (2006).
186. Siqueira IR, Fochesatto C, da Silva AL, Nunes DS, Battastini AM, Netto CA, et al. Ptychopetalum olacoides, a traditional Amazonian 'nerve tonic', possesses anticholinesterase activity. Pharmacol Biochem Behav 75: 645-50 (2003).
187. Elisabetsky E, Siqueira IR. Is there a psychopharmacological meaning for traditional tonics? In (Eds: Prendergast HD, Etkin N, Harris DR, Houghton PJ) Plants for Food and Medicine. Kew, London: Royal Botanic Gardens pp. 373-85 (1998).
188. Williamson EM. Potter's Herbal Cyclopedia. Saffron Walden: CW Daniel pp. 303 (2003).
189. Tang WX, Hioki H, Harada K, Kubo M, Fukuyama Y. Clerodane diterpenoids with NGF-potentiating activity from Ptychopetalum olacoides. J Nat Prod 71: 1760-63 (2008).
190. Tang WX, Kubo M, Harada K, Hioki H, Fukuyama Y. Novel NGFpotentiating diterpenoids from a Brazilian medicinal plant Ptychopetalum olacoides. Bioorg Med Chem Lett 19: 882-6 (2009).
191. da Silva AL, Piato ALS, Bardini S, Netto CA, Nunes DS, Elisabetsky E. Facilitating effects of Ptychopetalum olacoides Bentham (marapuama) on memory retrieval in young and old mice. J Ethnopharmacol 95: 199-203 (2004).
192. da Silva AL, Piato ALS, Ferreira JG, Martins BS, Nunes DS, Elisabetsky E. Promnesic effects of Ptychopetalum olacoides in aversive and non-aversive learning paradigms. J Ethnopharmacol 109: 449-57 (2007).
193. Figueiró M, Ilha J, Linck VM, Herrmann AP, Nardin P, Menezes CB, et al. The Amazonian herbal marapuama attenuates cognitive impairment and neuroglial degeneration in a mouse Alzheimer model. Phytomedicine 18: 327-33 (2011).
194. Siqueira IR, Cimarosti H, Fochesatto C, Nunes DS, Salbego C, Elisabetsky E, et al. Neuroprotective effects of Ptychopetalum olacoides Bentham (Olacaceae) on oxygen and glucose deprivationinduced damage in rat hippocampal slices. Life Sci 75: 1897-1906 (2004).
195. Figueiró M, Ilha J, Pochmann D, Porciuncula LO, Xavier LL, Achaval M, et al. Acetylcholinesterase inhibition in cognitionrelevant brain areas of mice treated with a nootropic Amazonian herbal (marpuama). Phytomedicine 17: 956-62 (2010).
196. da Silva AL, Ferreira JG, Martins BD, Oliviera S, Mai N, Nunes DS, et al. Serotonin receptors contribute to the promnesic effects of P. olacoides (marapuama) Physiol Behav 95: 88-92 (2008).
197. Eidi M, Eidi A, Bahar M. Effects of Salvia officinalis L. (sage) leaves on memory retention and its interaction with the cholinergic system in rats. Nutrition 22: 321-6 (2006).
198. Perry NSL, Houghton PJ, Theobald A, Jenner P, Perry EK. In vitro inhibition of human erythrocyte acetylcholinesterase by Salvia lavandulaefolia essential oil and constituent terpenes. J Pharm Pharmacol 52: 895-902 (2000).
199. Savelev S, Okello E, Perry NSL, Wilkins RM, Perry EK. Synergistic and antagonistic interactions of anticholinesterase terpenoids in Salvia lavandulaefolia essential oil. Pharmacol Biochem Behav 75: 661-8 (2003).
200. Perry NS, Houghton PJ, Jenner P, Keith A, Perry EK. Salvia lavandulaefolia essential inhibits cholinesterase in vivo. Phytomedicine 9: 48-51 (2002).
201. Perry NSL, Houghton PJ, Sampson J, Theobald AE, Hart S, Lis- Balchin M, et al. In vitro activities of S. lavandulaefolia (Spanish sage) relevant to treatment of Alzheimer's disease. J Pharm Pharmacol 53: 1347-56 (2001).
202. Hohmann J, Zupkó I, Rédei D, Csányi M, Falkay G, Máthé I, et al. Protective effects of the aerial parts of Salvia officinalis, Melissa officinalis and Lavandula angustifolia and their constituents against enzyme-dependent and enzyme-independent lipid peroxidation. Planta Med 65: 576-8 (1999).
203. Matsingou TC, Petrakis N, Kapsokefalou M, Salifoglou A. Antioxidant activity of organic extracts from aqueous infusions of sage. J Agric Food Chem 51: 6696-701 (2003).
204. Miura K, Kikuzaki H, Nakatani N. Antioxidant activity of chemical components from sage (Salvia officinalis L.) and thyme (Thymus vulgaris L.) measured by the oil stability index method. J Agric Food Chem 50: 1845-51 (2002).
205. Baricevic D, Sosa S, Della Loggia R, Tubaro A, Simonovska B, Krasna A, et al. Topical anti-inflammatory activity of Salvia officinalis L. leaves: The relevance of ursolic acid. J Ethnopharmacol 75: 125-32 (2001).
206. Iuvone T, De Filippis D, Esposito G, D'Amico A, Izzo AA. The spice sage and its active ingredient rosmarinic acid protect PC12 cells from amyloid-β peptide-induced neurotoxicity. J Pharmacol Exp Ther 317: 1143-9 (2006).
207. Tildesley NT, Kennedy DO, Perry EK, Ballard CG, Savelev S, Wesnes KA, et al. Salvia lavandulaefolia (Spanish sage) enhances memory in healthy young volunteers. Pharmacol Biochem Behav 75: 669-74 (2003).
208. Tildesley NT, Kennedy DO, Perry EK, Ballard CG, Wesnes KA, Scholey AB. Positive modulation of mood and cognitive performance following administration of acute doses of Salvia lavandulaefolia essential oil to healthy young volunteers. Physiol Behav 83: 699-709 (2005).
209. Perry NS, Bollen C, Perry EK, Ballard C. Salvia for dementia therapy: Review of pharmacological activity and pilot tolerability clinical trial. Pharmacol Biochem Behav 75: 651-9 (2003).
210. Akhondzadeh S, Noroozian M, Mohammadi M, Ohadinia S, Jamshidi AH, Khani M. Salvia officinalis extract in the treatment of patients with mild to moderate Alzheimer's disease: A double blind, randomized and placebo-controlled trial. J Clin Pharm Ther 28: 53-9 (2003).
211. Weng XC, Gordon MH. Antioxidant activity of quinones extracted from tanshen (Salvia miltiorrhiza Bung). J Agric Food Chem 40: 1331-6 (1992).
212. Liu GT, Zhang TM, Wang BE, Wang YW. Protective action of seven natural phenolic compounds against peroxidative damage to biomembranes. Biochem Pharmacol 43: 147-52 (1992).
213. Huang YS, Zhang JT. Antioxidative effect of three water-soluble components isolated from Salvia miltiorrhiza in vitro. Yao Xue Xue Bao 27: 96-100 (1992).
214. Du GH, Qiu Y, Zhang JT. Salvianolic acid B protects the memory functions against transient cerebral ischemia in mice. J Asian Nat Prod Res 2: 145-52 (2000).
215. Du G, Zhang J. Protective effects of salvianolic acid A against impairment of memory induced by cerebral ischemia-reperfusion in mice. Chin Med J 110: 65-8 (1997).
216. Lin YH, Liu AH, Wu HL, Westenbroek C, Song QL, Yu HM, et al. Salvianolic acid B, an antioxidant from Salvia miltiorrhiza, prevents Aβ(25-35)-induced reduction in BPRP in PC12 cells. Biochem Biophys Res Commun 348: 593-9 (2006).
217. Wang W, Zheng LL, Wang F, Hu ZL, Wu WN, Gu J, et al. Tanshinone IIA attenuates neuronal damage and the impairment of long-term potentiation induced by hydrogen peroxide. J Ethnopharmacol 134: 147-55 (2011).
218. Ren YH, Houghton PJ, Hider RC, Howes MJ. Novel diterpenoid acetylcholinesterase inhibitors from Salvia miltiorhiza. Planta Med 70: 201-4 (2004).
219. Wong KK, Ho MT, Lin HQ, Lau KF, Rudd JA, Chung RC, et al. Cryptotanshinone, an acetylcholinesterase inhibitor from Salvia miltiorrhiza, ameliorates scopolamine-induced amnesia in Morris water maze task. Planta Med 76: 228-34 (2010).
220. Yu XY, Lin SG, Chen X, Zhou ZW, Liang J, Duan W, et al. Transport of cryptotanshinone, a major active triterpenoid in Salvia miltiorrhiza Bunge widely used in the treatment of stroke and Alzheimer's disease, across the blood-brain barrier. Curr Drug Metab 8: 365-77 (2007).
221. Kuo YH, Lin YL, Don MJ, Chen RM, Ueng YF. Induction of cytochrome P450-dependent monooxygenase by extracts of the medicinal herb Salvia miltiorrhiza. J Pharm Pharmacol 58: 521-7 (2006).
222. Hu Z, Yang X, Ho PC, Chan SY, Heng PW, Chan E, et al. Herbdrug interactions: A literature review. Drugs 65: 1239-82 (2005).
223. Wu YT, Chen YF, Hsieh YJ, Jaw I, Shiao MS, Tsai TH. Bioavailability of salvianolic acid B in conscious and freely moving rats. Int J Pharm 326: 25-31 (2006).
224. Hao H, Wang G, Cui N, Li J, Xie L, Ding Z. Pharmacokinetics, absorption and tissue distribution of tanshinone IIA solid dispersion. Planta Med 72: 1311-7 (2006).